Theranostic designs of biomaterials for precision medicine in cancer therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyosuk | - |
dc.contributor.author | Kwak, Gijung | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.contributor.author | Yoon, Hong Yeol | - |
dc.contributor.author | Kwon, Ick Chan | - |
dc.date.accessioned | 2021-09-01T10:06:17Z | - |
dc.date.available | 2021-09-01T10:06:17Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-08 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/63621 | - |
dc.description.abstract | Theranostic biomaterials have been creating great new opportunities in developing precision medicine in cancer treatment. Moreover, there exist up-coming potentials to find a new paradigm change in cancer treatment when theranostic biomaterials can precisely image a biological process at the exact tumor sites. With aid of molecular imaging technology, theranostic biomaterials can visualize targets, monitor efficiency of delivery carriers as well as therapeutic responses at tumor site. Major obstacles in designing theranostic biomaterials might be what providing target-specificity to biomaterials for improving therapeutic efficacy as well as visualization in cancer treatment. By which, we can find ways to minimize unwanted side effects to normal tissues in cancer therapy. This review focuses on how theranostic biomaterials can be designed with tumor-specific fluorescence imaging probes, especially tumor-specific activatable imaging probes, which in turn can be switched to therapeutic design with identical principle. Highlights such as designing by characteristics of cancer, finding ways to monitor therapeutic efficacy, potential benefits in theranostic biomaterials are also discussed. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | AGGREGATION-INDUCED EMISSION | - |
dc.subject | IN-VIVO | - |
dc.subject | DRUG-DELIVERY | - |
dc.subject | MATRIX METALLOPROTEINASES | - |
dc.subject | BREAST-CANCER | - |
dc.subject | TUMOR UPTAKE | - |
dc.subject | PH | - |
dc.subject | NANOPARTICLES | - |
dc.subject | RECEPTOR | - |
dc.subject | PRODRUG | - |
dc.title | Theranostic designs of biomaterials for precision medicine in cancer therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kwangmeyung | - |
dc.identifier.doi | 10.1016/j.biomaterials.2019.05.018 | - |
dc.identifier.scopusid | 2-s2.0-85066424795 | - |
dc.identifier.wosid | 000472692400003 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, v.213 | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.citation.title | BIOMATERIALS | - |
dc.citation.volume | 213 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | AGGREGATION-INDUCED EMISSION | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | MATRIX METALLOPROTEINASES | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | TUMOR UPTAKE | - |
dc.subject.keywordPlus | PH | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | PRODRUG | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.